Metastatic melanoma patients with tissue BRAFWT signature and a molecular shift to circulating free DNA BRAF mutated positive melanomas upon progression to an anti PD-1 therapy MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864
Conditions
Interventions
Trade Name: Tafinlar
Product Name: Dabrafenib
Product Code: [Dabrafenib]
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: DABRAFENIB
CAS Number: 1195768-06-9
Current Sponsor code: Dabrafenib
Co
Sponsors
FONDAZIONE MELANOMA ONLUS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients of either sex aged = 18 years; 2) Histologically confirmed stage III (unresectable) or stage IV melanoma; 3) Tissue BRAFWT signature and a molecular shift to circulating free DNA BRAF mutated positive melanomas upon progression to anti PD-1 therapy; 4) Tumor biopsy, if feasible, to confirm the BRAFV600 mutation at progression; 5) Previous adjuvant treatment, including checkpoint inhibitors anti CTLA-4, anti PD-1/PDL-1 is allowed, except for stage IV (if completed at least 6 months prior to enrollment, and all related adverse events have either returned to baseline or stabilized). BRAF inhibitor treatment in adjuvant setting is not permitted; 6) Last previous treatment for metastatic disease MUST BE Anti-PD1 as single agent; 7) Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels; 8) Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria; 9) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2 (see Appendix II); 10) Female subjects of childbearing potential must have a negative pregnancy test result at baseline and must practice two highly effective methods of contraception for the duration of the study, EOT, at 30-day and 150-day safety follow up; 11) Sexually active males must agree to use effective contraception methods throughout treatment and for 150 days after stopping treatment and should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen; 12) Adequate baseline organ function as defined below: Hematologic ANC > 1.2 × 109/L Hemoglobin > 9 g/dL Platelet count > 75 x 109/L PT/INRa and PTT > 1.5 x ULN Hepatic Albumin > 2.5 g/dL Total bilirubin 50 mL/min Cardiac Left Ventricular Ejection fraction (LVEF) > LLN by ECHO a) Subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to enrolment. b) Calculate creatinine clearance using standard Cockcroft-Gault formula. Creatinine clearance must be >50 mL/min to be eligible. c) ECHO scans must be used throughout the study 13) Life expectancy of at least 3 months; 14) Ability to understand study-related patient information and provision of written informed consent for participation in the study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 35 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10
Exclusion criteria
Exclusion criteria: 1) Symptomatic brain metastases; 2) History of another malignancy, exception: subjects who have been disease-free for 3 years, (i.e. subjects with second malignancies that are indolent or definitively treated at least 3 years ago) or subjects with a history of completely resected non-melanoma skin cancer; 3) A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy including: • Presence of predisposing factors to RVO or central serous retinopathy (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes); or • Visible retinal pathology as assessed by ophthalmic examination that is considered a risk factor for RVO or central serous retinopathy such as: i. Evidence of new optic disc cupping; ii. Evidence of new visual field defects on automated perimetry; iii. Intraocular pressure >21 mmHg as measured by tonometry. 4) A history of clinically significant or active interstitial lung disease or pneumonitis; 5) Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject’s safety, obtaining informed consent, or compliance with study procedures; 6) Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted); 7) A history or evidence of cardiovascular risk including any of the following: • Current LVEF 480 msec; • A history or evidence of current clinically significant uncontrolled arrhythmias; Exception: Subjects with atrial fibrillation controlled for > 30 days prior to enrollment are eligible; • A history (within 6 months prior to enrollment) of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty; • A history or evidence of current >= Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines; • Treatment refractory hypertension defined as a blood pressure of systolic> 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti- hypertensive therapy; • Patients with intra-cardiac defibrillators or permanent pacemakers; • Known cardiac metastases; • Abnormal cardiac valve morphology (> grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study; • Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia, hypocalcaemia), long QT syndrome or taking medicinal products known to prolong the QT interval. 8) Female subjects who are pregnant (positive pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control; 9) Inability to regularly access site facilities for logistical or other reasons; 10) History of poor co-operation, non-compliance with medical treatment, or unreliability; 11) Participation in any interventional drug or medical device study within 30 days prior to treatment start.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The Overall Response Rate to Dabrafenib and Trametinib in BRAF wild type metastatic melanoma patients with a molecular shift to circulating free DNA BRAFV600 mutated upon progression to an anti PD-1 therapy.;Secondary Objective: 1. Total Progression Free Survival; 2. Overall Survival; 3. Toxicity of the investigational medicinal products (IMPs); 4. Quality of life by means of the 30-item European Organisation for Research and Treatment of Care quality of life questionnaire (EORTC QLQC30);;Primary end point(s): The Overall Response Rate to Dabrafenib and Trametinib in BRAF wild type metastatic melanoma patients with a molecular shift to circulating BRAFV600 mutated free DNA upon progression to an anti PD-1 therapy;Timepoint(s) of evaluation of this end point: Every 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Progression Free Survival (PFS) defined as the time from the date of first administration of therapy and the date of evidence of progression or death. 2. Overall Survival (OS) defined as the time from the date of first administration of therapy and the date of death from any cause. Any patient alive at the time of data analysis will be censored at the time of the last recorded date on which the patient was known to be alive. 3. Safety: the NCI CTC-AE (Version 5.0) will be used to evaluate the clinical safety of the treatment in this study; patients will be assessed for AEs at each clinical visit and as necessary throughout the study. 4. QoL: Health-related quality of life (HRQoL), by means of the 30-item European Organisation for Research and Treatment of Care quality of life questionnaire (EORTC QLQC30);Timepoint(s) of evaluation of this end point: 1. Every 12 weeks 2. Every 28 days during the treatment phase, every 12 months for 24 months during the follow-up phase 3. Continuously throughout the study 4. Every 12 weeks | — |
Countries
Italy
Contacts
Public ContactCRO
Clinical Research Technology
Outcome results
None listed